{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:17:08Z","timestamp":1787984228483,"version":"build-2784847793"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005874","name":"Universit\u00e0 degli Studi G. D'Annunzio Chieti Pescara","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005874","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diabetes mellitus is associated with a persistent prothrombotic state driven by platelet hyperreactivity, endothelial dysfunction, oxidative stress, and chronic low\u2011grade inflammation, all of which contribute to increased cardiovascular (CV) risk. Importantly, a substantial residual thrombotic risk persists even with optimal glycemic control, indicating that glucose lowering alone is insufficient to prevent vascular complications. In this context, antidiabetic therapies have emerged as important modulators of CV risk beyond their metabolic effects. Several drug classes\u2014including metformin, thiazolidinediones, DPP\u20114 inhibitors, SGLT\u20112 inhibitors, and GLP\u20111 receptor agonists\u2014have been shown to influence platelet activity, endothelial function, and inflammatory pathways. These effects are mediated through mechanisms such as enhanced nitric oxide bioavailability, reduced oxidative stress, attenuation of platelet activation, and modulation of vascular inflammation. Among these, GLP\u20111 receptor agonists exert particularly pronounced effects on endothelial function, oxidative stress, and platelet reactivity, alongside robust reductions in CV events. More broadly, accumulating experimental and clinical evidence indicates that several antidiabetic agents exert clinically meaningful antithrombotic actions, contributing to decreased rates of major CV events and heart failure. However, these benefits vary across drug classes and patient populations. This highlights the importance of an individualized therapeutic approach in type 2 diabetes, where treatment selection should account not only for glycemic targets but also for CV and thrombotic risk. Choosing agents with proven CV benefit may optimize overall risk reduction and improve long\u2011term outcomes. This narrative review aims to critically examine the available experimental and clinical evidence on the effects of antidiabetic drugs on platelet function, thrombosis, and thrombo-inflammatory pathways, highlighting the mechanisms that may contribute to cardiovascular protection beyond glucose lowering.<\/jats:p>","DOI":"10.1007\/s11739-026-04502-y","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:47:26Z","timestamp":1787982446000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antidiabetic medications and arterial thrombotic risk reduction: a narrative review"],"prefix":"10.1007","author":[{"given":"Francesca","family":"Santilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Liani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"4502_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41569-023-00877-z","volume":"20","author":"ND Wong","year":"2023","unstructured":"Wong ND, Sattar N (2023) Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol 20:685\u2013695. https:\/\/doi.org\/10.1038\/s41569-023-00877-z","journal-title":"Nat Rev Cardiol"},{"key":"4502_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1401569","volume":"11","author":"F Bouisset","year":"2024","unstructured":"Bouisset F, Bataille V, Schiele F et al (2024) Type 2 diabetes mellitus in acute myocardial infarction: a persistent significant burden on long-term mortality. Front Cardiovasc Med 11:1401569. https:\/\/doi.org\/10.3389\/fcvm.2024.1401569","journal-title":"Front Cardiovasc Med"},{"key":"4502_CR3","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1093\/eurheartj\/ehad260","volume":"44","author":"L Pennells","year":"2023","unstructured":"SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration, Pennells L, Kaptoge S et al (2023) SCORE2-diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J 44:2544\u20132556. https:\/\/doi.org\/10.1093\/eurheartj\/ehad260","journal-title":"Eur Heart J"},{"key":"4502_CR4","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.2337\/dc09-2013","volume":"33","author":"P Gresele","year":"2010","unstructured":"Gresele P, Marzotti S, Guglielmini G et al (2010) Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. Diabetes Care 33:1262\u20131268. https:\/\/doi.org\/10.2337\/dc09-2013","journal-title":"Diabetes Care"},{"key":"4502_CR5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1161\/01.cir.99.2.224","volume":"99","author":"G Dav\u00ec","year":"1999","unstructured":"Dav\u00ec G, Ciabattoni G, Consoli A et al (1999) In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99:224\u2013229. https:\/\/doi.org\/10.1161\/01.cir.99.2.224","journal-title":"Circulation"},{"key":"4502_CR6","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1007\/s13300-025-01801-z","volume":"16","author":"N Sharma","year":"2025","unstructured":"Sharma N, Verma SK, Sharma S et al (2025) Diabetic platelets: pathophysiology, clinical significance, and therapeutic perspectives. Diabetes Ther 16:2101\u20132109. https:\/\/doi.org\/10.1007\/s13300-025-01801-z","journal-title":"Diabetes Ther"},{"key":"4502_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12933-022-01517-5","volume":"21","author":"C Eyileten","year":"2022","unstructured":"Eyileten C, Wicik Z, Keshwani D et al (2022) Alteration of circulating platelet-related and diabetes-related microRNAs in individuals with type 2 diabetes mellitus: a stepwise hypoglycaemic clamp study. Cardiovasc Diabetol 21:79. https:\/\/doi.org\/10.1186\/s12933-022-01517-5","journal-title":"Cardiovasc Diabetol"},{"key":"4502_CR8","doi-asserted-by":"crossref","unstructured":"(1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854\u2013865","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"4502_CR9","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"ADVANCE Collaborative Group, Patel A, MacMahon S et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560\u20132572. https:\/\/doi.org\/10.1056\/NEJMoa0802987","journal-title":"N Engl J Med"},{"key":"4502_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa0808431","journal-title":"N Engl J Med"},{"key":"4502_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2337\/dc15-2283","volume":"39","author":"The ACCORD Study Group","year":"2016","unstructured":"The ACCORD Study Group (2016) Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. Diabetes Care 39:701\u2013708. https:\/\/doi.org\/10.2337\/dc15-2283","journal-title":"Diabetes Care"},{"key":"4502_CR12","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K et al (2023) 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 44:4043\u20134140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192","journal-title":"Eur Heart J"},{"key":"4502_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41569-018-0080-2","volume":"16","author":"G Patti","year":"2019","unstructured":"Patti G, Cavallari I, Andreotti F et al (2019) Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nat Rev Cardiol 16:113\u2013130. https:\/\/doi.org\/10.1038\/s41569-018-0080-2","journal-title":"Nat Rev Cardiol"},{"key":"4502_CR14","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"4502_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3173","volume":"35","author":"AV Zilov","year":"2019","unstructured":"Zilov AV, Abdelaziz SI, AlShammary A et al (2019) Mechanisms of action of metformin with special reference to cardiovascular protection. Diabetes Metab Res Rev 35:e3173. https:\/\/doi.org\/10.1002\/dmrr.3173","journal-title":"Diabetes Metab Res Rev"},{"key":"4502_CR16","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.2337\/dc24-S010","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee (2024) 10. Cardiovascular disease and risk management: standards of care in diabetes-2024. Diabetes Care 47:S179\u2013S218. https:\/\/doi.org\/10.2337\/dc24-S010","journal-title":"Diabetes Care"},{"key":"4502_CR17","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA et al (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577\u20131589. https:\/\/doi.org\/10.1056\/NEJMoa0806470","journal-title":"N Engl J Med"},{"key":"4502_CR18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1001\/archinternmed.2009.20","volume":"169","author":"A Kooy","year":"2009","unstructured":"Kooy A, de Jager J, Lehert P et al (2009) Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 169:616\u2013625. https:\/\/doi.org\/10.1001\/archinternmed.2009.20","journal-title":"Arch Intern Med"},{"key":"4502_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0021-9150(82)90069-7","volume":"41","author":"E Tremoli","year":"1982","unstructured":"Tremoli E, Ghiselli G, Maderna P et al (1982) Metformin reduces platelet hypersensitivity in hypercholesterolemic rabbits. Atherosclerosis 41:53\u201360. https:\/\/doi.org\/10.1016\/0021-9150(82)90069-7","journal-title":"Atherosclerosis"},{"key":"4502_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/srep36222","volume":"6","author":"G Xin","year":"2016","unstructured":"Xin G, Wei Z, Ji C et al (2016) Metformin uniquely prevents thrombosis by inhibiting platelet activation and mtDNA release. Sci Rep 6:36222. https:\/\/doi.org\/10.1038\/srep36222","journal-title":"Sci Rep"},{"key":"4502_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/dmrr.794","volume":"24","author":"G Formoso","year":"2008","unstructured":"Formoso G, De Filippis EA, Michetti N et al (2008) Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes Metab Res Rev 24:231\u2013237. https:\/\/doi.org\/10.1002\/dmrr.794","journal-title":"Diabetes Metab Res Rev"},{"key":"4502_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cca.2013.11.028","volume":"429","author":"LH Gon\u00e7alves","year":"2014","unstructured":"Gon\u00e7alves LH, Silva MVF, Duarte RCF et al (2014) Acetylsalicylic acid therapy: influence of metformin use and other variables on urinary 11-dehydrothromboxane B2 levels. Clin Chim Acta 429:76\u201378. https:\/\/doi.org\/10.1016\/j.cca.2013.11.028","journal-title":"Clin Chim Acta"},{"key":"4502_CR23","doi-asserted-by":"publisher","first-page":"9376","DOI":"10.7150\/thno.64706","volume":"11","author":"Y Ding","year":"2021","unstructured":"Ding Y, Zhou Y, Ling P et al (2021) Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function. Theranostics 11:9376\u20139396. https:\/\/doi.org\/10.7150\/thno.64706","journal-title":"Theranostics"},{"key":"4502_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01294-7","volume":"20","author":"L Nesti","year":"2021","unstructured":"Nesti L, Tric\u00f2 D, Mengozzi A, Natali A (2021) Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovasc Diabetol 20:109. https:\/\/doi.org\/10.1186\/s12933-021-01294-7","journal-title":"Cardiovasc Diabetol"},{"key":"4502_CR25","doi-asserted-by":"publisher","first-page":"880","DOI":"10.2337\/diabetes.54.3.880","volume":"54","author":"G Boden","year":"2005","unstructured":"Boden G, Homko C, Mozzoli M et al (2005) Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 54:880\u2013885. https:\/\/doi.org\/10.2337\/diabetes.54.3.880","journal-title":"Diabetes"},{"key":"4502_CR26","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJA et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279\u20131289. https:\/\/doi.org\/10.1016\/S0140-6736(05)67528-9","journal-title":"Lancet"},{"key":"4502_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ahj.2014.07.016","volume":"168","author":"CM Viscoli","year":"2014","unstructured":"Viscoli CM, Brass LM, Carolei A et al (2014) Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. Am Heart J 168:823-829.e6. https:\/\/doi.org\/10.1016\/j.ahj.2014.07.016","journal-title":"Am Heart J"},{"key":"4502_CR28","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","volume":"364","author":"RA DeFronzo","year":"2011","unstructured":"DeFronzo RA, Tripathy D, Schwenke DC et al (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364:1104\u20131115. https:\/\/doi.org\/10.1056\/NEJMoa1010949","journal-title":"N Engl J Med"},{"key":"4502_CR29","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457\u20132471. https:\/\/doi.org\/10.1056\/NEJMoa072761","journal-title":"N Engl J Med"},{"key":"4502_CR30","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","volume":"373","author":"PD Home","year":"2009","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125\u20132135. https:\/\/doi.org\/10.1016\/S0140-6736(09)60953-3","journal-title":"Lancet"},{"key":"4502_CR31","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.cardiores.2004.11.027","volume":"65","author":"D Li","year":"2005","unstructured":"Li D, Chen K, Sinha N et al (2005) The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 65:907\u2013912. https:\/\/doi.org\/10.1016\/j.cardiores.2004.11.027","journal-title":"Cardiovasc Res"},{"key":"4502_CR32","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2006.08.040","volume":"48","author":"S Basili","year":"2006","unstructured":"Basili S, Pacini G, Guagnano MT et al (2006) Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 48:2531\u20132538. https:\/\/doi.org\/10.1016\/j.jacc.2006.08.040","journal-title":"J Am Coll Cardiol"},{"key":"4502_CR33","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/193229681100500233","volume":"5","author":"T Sch\u00f6ndorf","year":"2011","unstructured":"Sch\u00f6ndorf T, Musholt PB, Hohberg C et al (2011) The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. J Diabetes Sci Technol 5:426\u2013432. https:\/\/doi.org\/10.1177\/193229681100500233","journal-title":"J Diabetes Sci Technol"},{"key":"4502_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000318024","volume":"116","author":"W Chokesuwattanaskul","year":"2010","unstructured":"Chokesuwattanaskul W, Yaqub Y, Suarez JA et al (2010) Effect of pioglitazone on platelet aggregation in a healthy cohort. Cardiology 116:253\u2013256. https:\/\/doi.org\/10.1159\/000318024","journal-title":"Cardiology"},{"key":"4502_CR35","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.thromres.2011.12.019","volume":"129","author":"J Mongan","year":"2012","unstructured":"Mongan J, Mieszczanska HZ, Smith BH et al (2012) Pioglitazone inhibits platelet function and potentiates the effects of aspirin: a prospective observation study. Thromb Res 129:760\u2013764. https:\/\/doi.org\/10.1016\/j.thromres.2011.12.019","journal-title":"Thromb Res"},{"key":"4502_CR36","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1124\/dmd.116.070375","volume":"44","author":"MK Itkonen","year":"2016","unstructured":"Itkonen MK, Tornio A, Neuvonen M et al (2016) Clopidogrel markedly increases plasma concentrations of CYP2C8 substrate pioglitazone. Drug Metab Dispos 44:1364\u20131371. https:\/\/doi.org\/10.1124\/dmd.116.070375","journal-title":"Drug Metab Dispos"},{"key":"4502_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10557-008-6091-1","volume":"22","author":"M Hanefeld","year":"2008","unstructured":"Hanefeld M, Schaper F, Koehler C (2008) Effect of acarbose on vascular disease in patients with abnormal glucose tolerance. Cardiovasc Drugs Ther 22:225\u2013231. https:\/\/doi.org\/10.1007\/s10557-008-6091-1","journal-title":"Cardiovasc Drugs Ther"},{"key":"4502_CR38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1475-2840-12-73","volume":"12","author":"M Zheng","year":"2013","unstructured":"Zheng M, Yang J, Shan C et al (2013) Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc Diabetol 12:73. https:\/\/doi.org\/10.1186\/1475-2840-12-73","journal-title":"Cardiovasc Diabetol"},{"key":"4502_CR39","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/jama.290.4.486","volume":"290","author":"J-L Chiasson","year":"2003","unstructured":"Chiasson J-L, Josse RG, Gomis R et al (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486\u2013494. https:\/\/doi.org\/10.1001\/jama.290.4.486","journal-title":"JAMA"},{"key":"4502_CR40","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/j.1538-7836.2010.03742.x","volume":"8","author":"F Santilli","year":"2010","unstructured":"Santilli F, Formoso G, Sbraccia P et al (2010) Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost 8:828\u2013837. https:\/\/doi.org\/10.1111\/j.1538-7836.2010.03742.x","journal-title":"J Thromb Haemost"},{"key":"4502_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1467-789X.2011.00930.x","volume":"13","author":"F Santilli","year":"2012","unstructured":"Santilli F, Vazzana N, Liani R et al (2012) Platelet activation in obesity and metabolic syndrome. Obes Rev 13:27\u201342. https:\/\/doi.org\/10.1111\/j.1467-789X.2011.00930.x","journal-title":"Obes Rev"},{"key":"4502_CR42","doi-asserted-by":"crossref","unstructured":"Ferroni P, Basili S, Falco A, Dav\u00ec G (2004) Platelet activation in type 2 diabetes mellitus. Journal of Thrombosis and Haemostasis","DOI":"10.1111\/j.1538-7836.2004.00836.x"},{"key":"4502_CR43","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.2337\/dc11-s206","volume":"34","author":"E Standl","year":"2011","unstructured":"Standl E, Schnell O, Ceriello A (2011) Postprandial hyperglycemia and glycemic variability. Diabetes Care 34:S120\u2013S127. https:\/\/doi.org\/10.2337\/dc11-s206","journal-title":"Diabetes Care"},{"key":"4502_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3132\/dvdr.2006.017","volume":"3","author":"PN B\u00e5venholm","year":"2006","unstructured":"B\u00e5venholm PN, Efendic S (2006) Postprandial hyperglycaemia and vascular damage - the benefits of acarbose. Diabetes Vasc Dis Res 3:72\u201379. https:\/\/doi.org\/10.3132\/dvdr.2006.017","journal-title":"Diabetes Vasc Dis Res"},{"key":"4502_CR45","doi-asserted-by":"publisher","first-page":"E568","DOI":"10.1152\/ajpendo.00297.2009","volume":"297","author":"MA Potenza","year":"2009","unstructured":"Potenza MA, Addabbo F, Montagnani M (2009) Vascular actions of insulin with implications for endothelial dysfunction. Am J Physiol Endocrinol Metab 297:E568-577. https:\/\/doi.org\/10.1152\/ajpendo.00297.2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4502_CR46","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1046\/j.1365-2125.1999.00092.x","volume":"48","author":"P King","year":"1999","unstructured":"King P, Peacock I, Donnelly R (1999) The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 48:643\u2013648. https:\/\/doi.org\/10.1046\/j.1365-2125.1999.00092.x","journal-title":"Br J Clin Pharmacol"},{"key":"4502_CR47","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545\u20132559. https:\/\/doi.org\/10.1056\/NEJMoa0802743","journal-title":"N Engl J Med"},{"key":"4502_CR48","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1136\/bmj.314.7093.1512","volume":"314","author":"K Malmberg","year":"1997","unstructured":"Malmberg K (1997) Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314:1512\u20131515. https:\/\/doi.org\/10.1136\/bmj.314.7093.1512","journal-title":"BMJ"},{"key":"4502_CR49","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"ORIGIN Trial Investigators","year":"2012","unstructured":"Trial Investigators ORIGIN, Gerstein HC, Bosch J et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319\u2013328. https:\/\/doi.org\/10.1056\/NEJMoa1203858","journal-title":"N Engl J Med"},{"key":"4502_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/dc13-2112","volume":"37","author":"DM Nathan","year":"2014","unstructured":"Nathan DM, DCCT\/EDIC Research Group (2014) The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 37:9\u201316. https:\/\/doi.org\/10.2337\/dc13-2112","journal-title":"Diabetes Care"},{"key":"4502_CR51","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/21224","volume":"399","author":"S Dimmeler","year":"1999","unstructured":"Dimmeler S, Fleming I, Fisslthaler B et al (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601\u2013605. https:\/\/doi.org\/10.1038\/21224","journal-title":"Nature"},{"key":"4502_CR52","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1161\/01.ATV.0000199519.37089.a0","volume":"26","author":"IA Ferreira","year":"2006","unstructured":"Ferreira IA, Mocking AIM, Feijge MAH et al (2006) Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 26:417\u2013422. https:\/\/doi.org\/10.1161\/01.ATV.0000199519.37089.a0","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4502_CR53","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.2337\/db11-1806","volume":"61","author":"G Spectre","year":"2012","unstructured":"Spectre G, \u00d6stenson C-G, Li N, Hjemdahl P (2012) Postprandial platelet activation is related to postprandial plasma insulin rather than glucose in patients with type 2 diabetes. Diabetes 61:2380\u20132384. https:\/\/doi.org\/10.2337\/db11-1806","journal-title":"Diabetes"},{"key":"4502_CR54","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/s0735-1097(02)02972-8","volume":"41","author":"P Gresele","year":"2003","unstructured":"Gresele P, Guglielmini G, De Angelis M et al (2003) Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 41:1013\u20131020. https:\/\/doi.org\/10.1016\/s0735-1097(02)02972-8","journal-title":"J Am Coll Cardiol"},{"key":"4502_CR55","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.2337\/db14-1729","volume":"64","author":"NG Joy","year":"2015","unstructured":"Joy NG, Tate DB, Younk LM, Davis SN (2015) Effects of acute and antecedent hypoglycemia on endothelial function and markers of atherothrombotic balance in healthy humans. Diabetes 64:2571\u20132580. https:\/\/doi.org\/10.2337\/db14-1729","journal-title":"Diabetes"},{"key":"4502_CR56","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrcardio.2012.183","volume":"10","author":"AJ Scheen","year":"2013","unstructured":"Scheen AJ (2013) Cardiovascular effects of gliptins. Nat Rev Cardiol 10:73\u201384. https:\/\/doi.org\/10.1038\/nrcardio.2012.183","journal-title":"Nat Rev Cardiol"},{"key":"4502_CR57","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317\u20131326. https:\/\/doi.org\/10.1056\/NEJMoa1307684","journal-title":"N Engl J Med"},{"key":"4502_CR58","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327\u20131335. https:\/\/doi.org\/10.1056\/NEJMoa1305889","journal-title":"N Engl J Med"},{"key":"4502_CR59","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.2337\/dc17-1091","volume":"40","author":"A Sharma","year":"2017","unstructured":"Sharma A, Green JB, Dunning A et al (2017) Causes of death in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease: insights from the TECOS trial. Diabetes Care 40:1763\u20131770. https:\/\/doi.org\/10.2337\/dc17-1091","journal-title":"Diabetes Care"},{"key":"4502_CR60","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1161\/CIRCULATIONAHA.118.038352","volume":"139","author":"DK McGuire","year":"2019","unstructured":"McGuire DK, Alexander JH, Johansen OE et al (2019) Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation 139:351\u2013361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038352","journal-title":"Circulation"},{"key":"4502_CR61","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3109\/09537104.2012.721907","volume":"23","author":"AK Gupta","year":"2012","unstructured":"Gupta AK, Verma AK, Kailashiya J et al (2012) Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. Platelets 23:565\u2013570. https:\/\/doi.org\/10.3109\/09537104.2012.721907","journal-title":"Platelets"},{"key":"4502_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3124","volume":"35","author":"I Cavallari","year":"2019","unstructured":"Cavallari I, Maddaloni E (2019) Cardiovascular effects of SGLT-2 inhibitors: what we have learned from cardiovascular outcome trials and what we still need to understand. Diabetes Metab Res Rev 35:e3124. https:\/\/doi.org\/10.1002\/dmrr.3124","journal-title":"Diabetes Metab Res Rev"},{"key":"4502_CR63","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"4502_CR64","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383:1425\u20131435. https:\/\/doi.org\/10.1056\/NEJMoa2004967","journal-title":"N Engl J Med"},{"key":"4502_CR65","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet"},{"key":"4502_CR66","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa427","author":"I Cavallari","year":"2020","unstructured":"Cavallari I, Maddaloni E, Pieralice S et al (2020) The vicious circle of left ventricular dysfunction and diabetes: from pathophysiology to emerging treatments. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa427","journal-title":"J Clin Endocrinol Metab"},{"key":"4502_CR67","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","volume":"13","author":"S Steven","year":"2017","unstructured":"Steven S, Oelze M, Hanf A et al (2017) The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol 13:370\u2013385. https:\/\/doi.org\/10.1016\/j.redox.2017.06.009","journal-title":"Redox Biol"},{"key":"4502_CR68","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12933-020-01016-5","volume":"19","author":"V Spigoni","year":"2020","unstructured":"Spigoni V, Fantuzzi F, Carubbi C et al (2020) Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events. Cardiovasc Diabetol 19:46. https:\/\/doi.org\/10.1186\/s12933-020-01016-5","journal-title":"Cardiovasc Diabetol"},{"key":"4502_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0750-8","volume":"17","author":"AR Aroor","year":"2018","unstructured":"Aroor AR, Das NA, Carpenter AJ et al (2018) Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovasc Diabetol 17:108. https:\/\/doi.org\/10.1186\/s12933-018-0750-8","journal-title":"Cardiovasc Diabetol"},{"key":"4502_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11101878","volume":"11","author":"P Pignatelli","year":"2022","unstructured":"Pignatelli P, Baratta F, Buzzetti R et al (2022) The sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce platelet activation and thrombus formation by lowering NOX2-related oxidative stress: a pilot study. Antioxidants (Basel) 11:1878. https:\/\/doi.org\/10.3390\/antiox11101878","journal-title":"Antioxidants (Basel)"},{"key":"4502_CR71","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2018.3024","volume":"319","author":"SL Zheng","year":"2018","unstructured":"Zheng SL, Roddick AJ, Aghar-Jaffar R et al (2018) Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 319:1580\u20131591. https:\/\/doi.org\/10.1001\/jama.2018.3024","journal-title":"JAMA"},{"key":"4502_CR72","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMra2500106","volume":"394","author":"CJ Rosen","year":"2026","unstructured":"Rosen CJ, Ingelfinger JR (2026) GLP-1 receptor agonists. N Engl J Med 394:1313\u20131324. https:\/\/doi.org\/10.1056\/NEJMra2500106","journal-title":"N Engl J Med"},{"key":"4502_CR73","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS et al (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7:776\u2013785. https:\/\/doi.org\/10.1016\/S2213-8587(19)30249-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4502_CR74","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Pavo I, Bhatt DL et al (2025) Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med 393:2409\u20132420. https:\/\/doi.org\/10.1056\/NEJMoa2505928","journal-title":"N Engl J Med"},{"key":"4502_CR75","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.peptides.2018.09.002","volume":"111","author":"M Almutairi","year":"2019","unstructured":"Almutairi M, Al Batran R, Ussher JR (2019) Glucagon-like peptide-1 receptor action in the vasculature. Peptides 111:26\u201332. https:\/\/doi.org\/10.1016\/j.peptides.2018.09.002","journal-title":"Peptides"},{"key":"4502_CR76","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1111\/bph.13549","volume":"174","author":"S Steven","year":"2017","unstructured":"Steven S, Jurk K, Kopp M et al (2017) Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice. Br J Pharmacol 174:1620\u20131632. https:\/\/doi.org\/10.1111\/bph.13549","journal-title":"Br J Pharmacol"},{"key":"4502_CR77","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.2337\/dc12-2469","volume":"36","author":"A Ceriello","year":"2013","unstructured":"Ceriello A, Novials A, Ortega E et al (2013) Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 36:2346\u20132350. https:\/\/doi.org\/10.2337\/dc12-2469","journal-title":"Diabetes Care"},{"key":"4502_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/nu10121872","volume":"10","author":"P Simeone","year":"2018","unstructured":"Simeone P, Liani R, Tripaldi R et al (2018) Thromboxane-dependent platelet activation in obese subjects with prediabetes or early type 2 diabetes: effects of liraglutide- or lifestyle changes-induced weight loss. Nutrients 10:1872. https:\/\/doi.org\/10.3390\/nu10121872","journal-title":"Nutrients"},{"key":"4502_CR79","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12933-025-02706-8","volume":"24","author":"PG Simeone","year":"2025","unstructured":"Simeone PG, Costantino S, Liani R et al (2025) Interleukin-1\u03b2 in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes. Cardiovasc Diabetol 24:247. https:\/\/doi.org\/10.1186\/s12933-025-02706-8","journal-title":"Cardiovasc Diabetol"},{"key":"4502_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01469-w","volume":"21","author":"P Simeone","year":"2022","unstructured":"Simeone P, Tripaldi R, Michelsen A et al (2022) Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss. Cardiovasc Diabetol 21:36. https:\/\/doi.org\/10.1186\/s12933-022-01469-w","journal-title":"Cardiovasc Diabetol"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04502-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04502-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04502-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:47:28Z","timestamp":1787982448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-026-04502-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":80,"alternative-id":["4502"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04502-y","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prof Santilli has received research grant support and consulting fees from Bayer. The remaining authors have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is a review of previously published literature and does not report any original studies involving human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Human and Animal Rights","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is a review of previously published literature and does not involve the enrollment of human participants or the collection of identifiable personal data.","order":3,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}